Lu AE58054

Lu AE58054

(IUPAC) ime
2-(6-fluoro-1H-indol-3-il)-N-(3-(2,2,3,3,3-pentafluoropropoksi)benzil)etanamin
Klinički podaci
Identifikatori
CAS broj	467459-31-0
ATC kod	nije dodeljen
PubChem[1][2]	71587742
Hemijski podaci
Formula	C20H19F5N2O
Mol. masa	398,37 g/mol
SMILES	eMolekuli & PubHem
InChI InChI=1S/C20H18F6N2O/c21-15-4-5-17-14(11-28-18(17)9-15)6-7-27-10-13-2-1-3-16(8-13)29-12-19(22,23)20(24,25)26/h1-5,8-9,11,27-28H,6-7,10,12H2^Y Key: LIXYCQPIKCLHMF-UHFFFAOYSA-N^Y
Sinonimi	Lu-AE-58054
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Lu AE58054 je potentan i selektivan antagonist 5-HT₆ receptora. On je u razvoju kao augmentaciona terapija za tretman kognitivnih deficita vezanih za Alchajmerovu bolest i šizofreniju.^[3][4][4]

References

1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
3. „U.S. Development Programs. - Lundbeck”. 
4. „Search of: Lu AE58054 - List Results - ClinicalTrials.gov”. 

Spoljašnje veze

	Portal Medicina
	Portal Hemija

• Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia Arhivirano 2011-07-09 na Wayback Machine-u
• Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease Arhivirano 2010-02-04 na Wayback Machine-u